BioCentury | Jan 19, 2018
Company News

Context acquires onapristone from Arno

...endometrial and breast cancers. Arno held exclusive, worldwide rights to develop and commercialize onapristone from Invivis Pharmaceuticals Inc....
BioCentury | Jul 21, 2017
Company News

Management tracks

...company Context Therapeutics (Philadelphia, Pa.) named Erard Gilles CMO. He was founder and CMO at Invivis Pharmaceuticals Inc....
BioCentury | Jan 12, 2017
Clinical News

Onapristone: Ph II halted

...a 2012 deal (see BioCentury, Feb. 20, 2012 ). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
...recommended Phase II dose; safety and pharmacokinetics Status: Phase II halted Milestone: NA Julian Zhu onapristone Arno Therapeutics Inc. Invivis Pharmaceuticals Inc. Progestin...
BioCentury | Apr 25, 2016
Clinical News

Onapristone: Phase I/II discontinued

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Aug 24, 2015
Clinical News

Onapristone ER: Phase I/II amended

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Jul 20, 2015
Clinical News

Onapristone: Additional Phase I data

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Jul 20, 2015
Clinical News

Onapristone ER: Phase I data

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | May 11, 2015
Clinical News

Onapristone: Phase I data

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Apr 14, 2014
Clinical News

Onapristone ER: Phase I/II started

...under a license from BTG plc (LSE:BTG, London, U.K.). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Jan 27, 2014
Clinical News

Onapristone: Phase I started

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
Items per page:
1 - 10 of 15
BioCentury | Jan 19, 2018
Company News

Context acquires onapristone from Arno

...endometrial and breast cancers. Arno held exclusive, worldwide rights to develop and commercialize onapristone from Invivis Pharmaceuticals Inc....
BioCentury | Jul 21, 2017
Company News

Management tracks

...company Context Therapeutics (Philadelphia, Pa.) named Erard Gilles CMO. He was founder and CMO at Invivis Pharmaceuticals Inc....
BioCentury | Jan 12, 2017
Clinical News

Onapristone: Ph II halted

...a 2012 deal (see BioCentury, Feb. 20, 2012 ). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
...recommended Phase II dose; safety and pharmacokinetics Status: Phase II halted Milestone: NA Julian Zhu onapristone Arno Therapeutics Inc. Invivis Pharmaceuticals Inc. Progestin...
BioCentury | Apr 25, 2016
Clinical News

Onapristone: Phase I/II discontinued

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Aug 24, 2015
Clinical News

Onapristone ER: Phase I/II amended

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Jul 20, 2015
Clinical News

Onapristone: Additional Phase I data

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Jul 20, 2015
Clinical News

Onapristone ER: Phase I data

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | May 11, 2015
Clinical News

Onapristone: Phase I data

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Apr 14, 2014
Clinical News

Onapristone ER: Phase I/II started

...under a license from BTG plc (LSE:BTG, London, U.K.). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
BioCentury | Jan 27, 2014
Clinical News

Onapristone: Phase I started

...under a 2012 deal (see BioCentury, Feb. 20, 2012). Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc....
Items per page:
1 - 10 of 15